AptaBio Therapeutics Inc. (KOSDAQ:293780)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,460.00
-160.00 (-2.42%)
Sep 4, 2026, 3:30 PM KST

AptaBio Therapeutics Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-14,869-16,346-29,378-12,062-10,565
Depreciation & Amortization
435.38480.81531.35539.11484.62
Asset Writedown & Restructuring Costs
475.11475.11---
Loss (Gain) From Sale of Investments
688.76-0.28583.55244.292,494
Loss (Gain) on Equity Investments
-1,2702,653625.934.19-
Stock-Based Compensation
157.89211.51234.34186.65123.6
Provision & Write-off of Bad Debts
341.99373.63---
Other Operating Activities
-2,153455.7412,436-2,458631.31
Change in Accounts Receivable
269.02159.35-893.71--
Change in Inventory
20.2139.54-224.87--
Change in Accounts Payable
-20.7231.841.87--
Change in Other Net Operating Assets
-1,448-3,8103,924-549.77-1.91
Operating Cash Flow
-17,373-15,276-12,160-14,095-6,833
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Capital Expenditures
-30.87-58.67-240.16-1,345-1,041
Sale of Property, Plant & Equipment
1,4001,400---
Cash Acquisitions
2,000130.49---
Sale (Purchase) of Intangibles
----46.6-10.36
Sale (Purchase) of Real Estate
-----65.94
Investment in Securities
9,3566,90713,521-9,0065,332
Other Investing Activities
-2,029-2,029-55.6260.1527.66
Investing Cash Flow
10,7266,48912,854-12,7371,743

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Long-Term Debt Issued
---38,900-
Long-Term Debt Repaid
--661.25-134.01-127.85-87.95
Net Debt Issued (Repaid)
-180.71-661.25-134.0138,772-87.95
Issuance of Common Stock
----589.2
Other Financing Activities
-16.42-17.45-33.3-19.2-5.24
Financing Cash Flow
-197.13-678.7-167.3149,854496.01

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Foreign Exchange Rate Adjustments
3.913.28-1.195.0716.76
Miscellaneous Cash Flow Adjustments
00-0-00
Net Cash Flow
-6,840-9,463525.3323,027-4,577

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-17,404-15,335-12,400-15,440-7,874
Free Cash Flow Growth
-----
Free Cash Flow Margin
-366.15%-414.69%-368.94%-4767.39%-16284.04%
Free Cash Flow Per Share
-633.29-569.90-526.76-692.42-353.27
Levered Free Cash Flow
-20,880-21,959-1,924-13,398-
Unlevered Free Cash Flow
-19,818-20,635201.3-12,659-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash Interest Paid
7.418.4310.211.474.49
Cash Income Tax Paid
--152.5576.1848.45-34.01
Change in Working Capital
-1,180-3,5792,807-549.77-1.91